New psychoactive substances (NPS) are a heterogeneous group of substances. They are
associated with a number of health and social harms on an individual and societal level …

Objectives A critical evaluation of the scientific literature is necessary to delineate the risks of
ST when combining psychedelics with available serotonergic pharmacotherapy options …

The emergence of new psychoactive substances has earned a great deal of attention, and
several reports of acute poisoning and deaths have been issued involving, for instance …

This work comprehensively reviews some fundamental concepts about drugs, especially
focusing on new psychoactive substances (NPS), and their typical classifications based on …

Abstract Cannabinoid receptors type 1 (CB 1) and type 2 (CB 2) are promising targets for a
number of diseases, including obesity, neuropathic pain, and multiple sclerosis, among …

As recreational substances, synthetic cathinones started to be used at the beginning of the
21st century. There is still limited data on these compounds, introduced to the illicit drug …

The ever‐growing number of novel psychoactive substances (NPS) that have been
surfacing globally, as well as related changes in drug abuse trends, undoubtedly constitute …

The use of recreational drugs, including new psychoactive substances (NPS), is paralleled
by emergency department visits of drug users with severe cardiotoxicity. Drug-induced …

Psychedelic and stimulating phenethylamines belong to the family of new psychoactive
substances (NPS). The acute toxicity framework has begun to be investigated, while studies …

Serotonergic psychedelics, substances exerting their effects primarily through the serotonin
2A receptor (5-HT 2A R), continue to comprise a substantial portion of reported new …